Think Bioscience, a Boulder, CO-based synthetic biology company focused on developing small-molecule therapeutics that target “undruggable” proteins, raised a $6M Seed extension funding.
YK Bioventures joined existing investors, bringing total funding to $26M.
The additional raise will accelerate the company’s pipeline.
Led by Dr. Jerome Fox, co-founder and CEO, Think Bioscience is reimagining synthetic biology by using living systems to guide the design and assembly of medicines. The company programs microbes to build small molecules that bind to functional pockets, and they use these pockets to find hits in drug-like space. The platform technology has been expanded to protein tyrosine phosphatases (PTPs), kinases (PTKs), proteases, and GTPases.
Dr. Wendy Young will join the Board of Directors, which includes fellow veteran drug developer Nick Saccomano. Dr. Young has held leadership positions in biopharma for over 30 years and most recently spent 15 years at Genentech where she served as Senior Vice President of Small Molecule Drug Discovery and co-led research. She currently serves as a SAB member to Think, as well as several other biotech companies, and is an advisor at Google Ventures.
FinSMEs
07/05/2024